Feature articles on Big Pharma:

Health: Big Pharma "Doomed" if it Doesn't Change, Says Eli Lilly Chairman
(NaturalNews) With patents set to expire on major products and no new blockbusters on the horizon, the pharmaceutical industry must adapt or die, the chairman of Eli Lilly & Co. has said. "I think the industry is doomed if we don't change." said Sidney Taurel.

The expiration of patents on top moneymaking drugs is expected to reduce the top drug companies' profits by a total of $67 billion between 2007 and 2012, or 50 percent of those companies' combined 2007 sales in the United States. This decline in income is expected to be the industry's first in 40 years.

Once a drug's patent expires after 20 years, the market is opened up to generic versions, which are typically sold at a cost close to that of production, in contrast to the 90 or 95 percent profit margins enjoyed by patent-protected drugs. Once the patent expired on Merck's cholesterol drug Zocor, for example, the company's revenues from the drug dropped an estimated 82 percent.

Drugs set to go generic by 2012 include Lipitor, the best-selling drug in history, which grossed Pfizer $13 billion in 2006. Also due to lose their patent protection are asthma medication Singulair, blood-pressure drug Cozaar, and osteoporosis drug Fosamax, which currently bring in 44 percent of Merck's income.

Meanwhile, no new drugs have emerged on the horizon to take the place of these money-makers. Compared with 1995-1999, 43 percent fewer new drugs came to market between 2002 and 2006.

"There haven't been any new therapies that are proven to reduce death and disability for atherosclerosis since the introduction of the statins in the late 1980s," said Richard C. Pasternak, Merck's vice president of Cardiovascular Clinical Research.

As a result, Moody's Investors Service has lowered the pharmaceutical industry's outlook from "stable" to "negative," and investment has dropped drastically.

Many in the pharmaceutical industry are hoping to shift their focus to biotechnology, where the laws currently do not allow the development of generic drugs. High-grossing biotech drugs include cancer drug Avastin, which costs $4,400 per month, and Gaucher disease treatment Cerezyme, which costs $200,000 per year.

See all 159 Big Pharma feature articles.

 Concept-related articles:

modern medicine:

• Acupuncture proven effective at treating post-operative nausea; but modern medicine marginalizes true potential of acupuncture
• Is Modern Medicine Founded on Error?
• If prescription drugs are so good, where are all the healthy drug takers?
• A Plan for Living a Long and Healthy Life (Part 1)

• Massive medical fraud exposed: pharmaceutical company paid doctors to prescribe drugs and run sham clinical trials

• Review: The Best Tasting Green Superfood Powder Products

• Mandatory AIDS testing proposal is public health lunacy

• Despite the claims of the mainstream media, Lesco and other statins are not magic bullets for cholesterol

• Bone density sharply enhanced by weight training, even in the elderly

• Depression, Osteoporosis Correlation Misreported by Junk Science Media, Ill-Informed Health Researchers

• If prescription drugs are so good, where are all the healthy drug takers?

• Q & A: Are there any situations in which pharmaceuticals and medications are okay to use?

• The great direct-to-consumer prescription drug advertising con: how patients and doctors alike are easily influenced to demand dangerous drugs

• Health care costs are bankrupting employers, employees, surveys find

• The FDA Exposed: An Interview With Dr. David Graham, the Vioxx Whistleblower

• Unnecessary surgery exposed! Why 60% of all surgeries are medically unjustified and how surgeons exploit patients to generate profits

• The great direct-to-consumer prescription drug advertising con: how patients and doctors alike are easily influenced to demand dangerous drugs

• Big Pharma and profit priorities: why business ethics never trickle up

permanent link